International Symposium on
IL-6: PHYSIOPATHOLOGY AND CLINICAL POTENTIALS
Le Montreux Palace, Montreux, Switzerland
October 21-23, 1991

Aim of the Meeting

Interleukin 6 is a mediator of the body response to pathogenic aggressions such as tissue injuries, traumatic shock, infections by bacteria or viruses, and cancers. The conference will focus on the role of IL-6 in the acute phase seem response, in the immune response of T and B cells, in hematopoiesis and myeloid differentiation, and in growth regulation of tumor cells. The main topics will be the mechanism of action of IL-6, its therapeutic potential, involvement in diseases and the regulation of its production and action.

Scientific Secretary:

M. Revel, Department of Molecular Genetics and Virology,
The Weizmann Institute of Science, Rehovot 76100, Israel
Tel. (8) 342101-343242, Tlx 381300, Fax (8) 466966

Useful Information:

Registration fee: USD 250.00. A limited number of free communications will be accepted for oral or poster presentation. Abstracts must be sent to M. Revel before June 1st, 1991 (postmarked).

For further information, please contact
Ares-Serono Symposia
Via Ravenna 8
00161 Rome Italy,
Tel. 423328-428422/7/9
Tlx 621690, Fax (6) 423767.

ANNOUNCEMENT

A Workshop on

NEOPLASTIC TRANSFORMATION IN HUMAN CELL SYSTEMS IN VITRO:
MECHANISMS OF CARCINOGENESIS

April 25-26, 1991

Georgetown University Medical Center
Washington, DC 20007

Organizers:

J.S. Rhim and A. Dritschilo, Co-Chairmen
G. Jay, J. Little, J. McCormick, R. Tennant, and R.R. Weichselbaum

The role of carcinogenic agents in the development of human cancers is being defined using a variety of human cell as experimental model systems. The aims of this workshop are to present the state-of-the-art in transformation of human cells in culture and to provide insights into the molecular and cellular changes involved in the conversion of normal cells to a neoplastic state of growth.

Topics:

2. Factors involved in modulating cellular transformation.
3. Usefulness of in vitro model systems for viral, chemical, and radiation carcinogenesis.
5. Role of activated and suppressor oncogenes in neoplastic transformation.

Speakers:


Abstracts: Abstracts for poster presentations should be submitted on forms available upon request. The deadline for submission is January 15, 1991.

Correspondence should be sent to Ms. Sandra Hawkins, Department of Radiation Medicine, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007; Tel: 202-687-2144, Fax: 202-784-3323.
AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Membrane Transport in Multidrug Resistance, Development, and Disease
(co-sponsored by the National Cancer Institute of Canada)

March 10-14, 1991
Banff Centre, Banff, Alberta, Canada

CONFERENCE COCHAIRPERSONS

SUSAN B. HORWITZ / Bronx, NY  VICTOR LING / Toronto, Ontario, Canada

PROGRAM COMMITTEE

GIOVANNA F.-L. AMES / Berkeley, CA  CAROL E. CASS / Edmonton, Alberta, Canada
ANNA MARIA CASAZZA / Wallingford, CT  PHILIPPE GROS / Montreal, Quebec, Canada
JOHN RIORDAN / Toronto, Ontario, Canada

SCIENTIFIC PROGRAM

The Future of Medical Genetics
VICTOR LING / Toronto, Canada
LOUIS SIMINOVITCH / Toronto, Canada

Phosphorylation and Signal Transduction
I. BERNARD WEINSTEIN / New York, NY
DAVID L. GARBERS / Nashville, TN
RANDALL R. REED / Baltimore, MD

Membrane Pumps and Channels
WILLIAM T. BECK / Memphis, TN
WILLIAM A. CATTERALL / Seattle, WA
HARVEY F. LODISH / Cambridge, MA
REINHART A. F. REITHMEIER / Toronto, Canada

Multidrug Resistance
SUSAN B. HORWITZ / Bronx, NY
IGOR B. RONINSON / Chicago, IL
TAKASHI TSURUO / Tokyo, Japan
MICHAEL M. GOTTESMAN / Bethesda, MD
BRUCE A. CHABNER / Bethesda, MD

The Cystic Fibrosis Gene and its Product
RICHARD BOUCHER / Chapel Hill, NC
LAP-CHEE TSUI / Toronto, Canada
MICHAEL J. WELSH / Iowa City, IA
JOHN R. RIORDAN / Toronto, Canada

P-Glycoprotein Homologs and Development
PHILIPPE GROS / Montreal, Canada
PIET BORST / Amsterdam, Netherlands
JEREMY THORNER / Berkeley, CA
JAMES M. CROOP / Boston, MA
ALAN COWMAN / Melbourne, Australia

Metabolites and Drug Transport
ALAN R. P. PATERSON / Edmonton, Canada
CAROL E. CASS / Edmonton, Canada
I. DAVID GOLDMAN / Richmond, VA
STEPHEN B. HOWELL / La Jolla, CA
SHIMON SCHULDINER / Jerusalem, Israel

Permease Systems in Bacteria and Eukaryotes
ERNEST M. WRIGHT / Los Angeles, CA
GIOVANNA F.-L. AMES / Berkeley, CA
H. RONALD KABACK / Los Angeles, CA

Information and Application Forms
American Association for Cancer Research
Public Ledger Building, Suite 816
Sixth and Chestnut Streets
Philadelphia, PA 19106
215-440-9300  215-440-9313 (FAX)

Application Deadline:
December 3, 1990

Late applications will be accepted on a space-available basis.
This issue’s cover features the immediate Past President of the American Association for Cancer Research. Harris Busch received the M.D. degree from the University of Illinois College of Medicine in 1946. After internship at the Cook County Hospital, Chicago, in 1946, with fellowships from the United States Public Health Service and the National Cancer Institute, 1950–1952, he earned his Ph.D. at the University of Wisconsin McArdle Laboratory for Cancer Research in 1952. He joined the Yale University School of Medicine as assistant professor of biochemistry and Baldwin scholar in oncology and, in 1955, transferred to the University of Illinois College of Medicine as associate professor of pharmacology, rising to professor in 1959. He was then appointed professor of pharmacology and department chairman at Baylor University College of Medicine in 1960. In 1968 he was made director of the cancer program at Baylor and in 1978 was awarded a Distinguished Service Professorship. After serving the Association in many capacities, he was elected President in 1989. A hallmark of his Presidency was his vigorous emphasis on strengthening the role of the Public Education Committee in educating members of Congress about the progress in cancer research and the need for substantial research support. He formed the AACR network of State Legislative Committees who have been very active in communicating with their elected officials in each state about the funding crisis.

Harris Busch has had an incredibly active career in the basic molecular biology of cancer and pharmacology, with almost 900 original papers, reviews, books, and book chapters to his credit. His wide-ranging research interests focused largely on the study of the nucleolus, toward which he made pioneering contributions; on nuclear proteins; and on RNA. In 1978, he was cited as one of the 300 most quoted authors. He has run the gamut of officerships, committees, and editorships in national and international professional activities and has received numerous awards and lectureships.

Among his many contributions to nuclear structure, Harris Busch is perhaps best known for his discovery and identification of the “RNA caps” and a family of nuclear and cytoplasmic RNAs enriched in uridylic acid (J. Biol. Chem., 243: 6334–6342, 1968) that are involved in processing of mRNA, rRNA, protein transport, and other cellular functions (Annu. Rev. Biochem., 51: 617–654, 1982).

Among other notable initiatives, he has been a superb, articulate spokesperson and advocate of federal cancer research funding.

Sidney Weinhouse